- Home
- ANEB vs PMN Comparison
ANEB vs PMN Comparison
Compare ANEB & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANEB
- PMN
- Stock Information
- Founded
- ANEB 2020
- PMN 2004
- Country
- ANEB United States
- PMN Canada
- Employees
- ANEB N/A
- PMN N/A
- Industry
- ANEB Biotechnology: Pharmaceutical Preparations
- PMN Pharmaceuticals and Biotechnology
- Sector
- ANEB Health Care
- PMN Health Care
- Exchange
- ANEB Nasdaq
- PMN Nasdaq
- Market Cap
- ANEB 39.0M
- PMN 17.0M
- IPO Year
- ANEB 2021
- PMN N/A
- Fundamental
- Price
- ANEB $1.36
- PMN $0.49
- Analyst Decision
- ANEB Strong Buy
- PMN Strong Buy
- Analyst Count
- ANEB 2
- PMN 2
- Target Price
- ANEB $5.50
- PMN $4.50
- AVG Volume (30 Days)
- ANEB 11.2K
- PMN 39.5K
- Earning Date
- ANEB 05-13-2025
- PMN 08-07-2025
- Dividend Yield
- ANEB N/A
- PMN N/A
- EPS Growth
- ANEB N/A
- PMN N/A
- EPS
- ANEB N/A
- PMN N/A
- Revenue
- ANEB N/A
- PMN N/A
- Revenue This Year
- ANEB N/A
- PMN N/A
- Revenue Next Year
- ANEB N/A
- PMN N/A
- P/E Ratio
- ANEB N/A
- PMN N/A
- Revenue Growth
- ANEB N/A
- PMN N/A
- 52 Week Low
- ANEB $0.80
- PMN $0.47
- 52 Week High
- ANEB $3.08
- PMN $2.37
- Technical
- Relative Strength Index (RSI)
- ANEB 60.12
- PMN 45.60
- Support Level
- ANEB $1.31
- PMN $0.48
- Resistance Level
- ANEB $1.47
- PMN $0.53
- Average True Range (ATR)
- ANEB 0.14
- PMN 0.02
- MACD
- ANEB 0.00
- PMN 0.00
- Stochastic Oscillator
- ANEB 60.32
- PMN 26.86
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.